Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Donate to Science & Enterprise

Please share Science & Enterprise

Precision Antibacterial Company Raises $35M in New Funds

E. coli bacteria

E. coli bacteria (Agricultural Research Service, USDA)

18 May 2022. A biotechnology company creating targeted antibacterial and microbiome treatments aided by gene editing is raising $35 million in new venture funds. Locus Biosciences Inc. is a developer of antibiotics using synthetic biology and the gene editing technology Crispr to treat bacterial infections, as well as treatments for other diseases influenced by bacterial activity.

Locus Bio, a seven year-old enterprise in Morrisville, North Carolina, says it engineers viruses called bacteriophages, or phages, natural enemies of bacteria that infect and replicate inside bacteria, where the viruses produce lysin enzymes. These enzymes then break down the walls of bacterial cells, destroying the bacteria. The company says it combines high-throughput drug discovery processes with artificial intelligence to find phages with the needed properties to combat specific bacteria, then designs a collection of phages for each target.

In addition, says Locus Bio, its technology uses the gene-editing technique Crispr to destroy bacteria targeted by engineered phages. Crispr — short for clustered, regularly interspaced short palindromic repeats — edits the genomes of organisms with bacterial defense mechanisms using RNA to identify and monitor precise locations in DNA. In most gene editing cases, Crispr uses enzymes like Cas9 that cut DNA at precise locations. Locus Bio, however, says it replaces Cas9 with the enzyme Cas3, which shreds DNA beyond repair, killing bacterial cells.

Evidence of lower E. coli levels

The company’s lead product, code-named LBP-EC01, is a treatment for urinary tract infections or UTIs caused by e. coli bacteria. UTIs occur most often among women, in the bladder and urethra. If left untreated, these infections can spread to the kidneys or beyond with serious consequences. National Kidney Foundation says urinary tract infections are responsible for some 10 million doctor visits a year in the U.S., with at least 1 in 5 women likely to have an infection in her lifetime.

Locus Bio conducted an early-stage clinical trial of LBP-EC01, completed last year, which the company says met all of its safety objectives and shows evidence of lower E. coli levels in the bladders of UTI patients. Science & Enterprise reported on the start of the trial in Jan. 2020. Locus Bio says it has other products in its pipeline in preclinical development that address diseases of the microbiome, communities of bacteria and other microbes in the body, many of which are essential to good health.

The company is raising $35 million in its second venture funding round with investors that include Artis Ventures, Tencent Holdings, Viking Global Investors, Johnson and Johnson Innovation, and Discovery Innovations. Locus Bio is collaborating with Janssen Pharmaceuticals, a division of Johnson & Johnson, in developing LBP-EC01. The new financing includes a convertible note that converts a previous loan to equity. According to Crunchbase, Locus Bio raised $93.7 million in earlier rounds.

The company says in a statement it plans to apply the new funds to a mid- and late-stage clinical trial of LBP-EC01 and preclinical work on microbiome diseases, as well as further develop its manufacturing facilities. Locus Bio says its manufacturing plant is a self-contained facility for making viral therapeutics, which the company wants to enhance for producing solid-dose oral drugs.

More from Science & Enterprise:

Disclosure: the author owns shares in Johnson & Johnson

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the entire page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Companies Partner on Implanted Diabetes Beta Cell Device

Diabetes blood glucose test

(Amanda Mills, CDC.gov)

17 May 2022. A company developing implants that release cell therapies is collaborating with a producer of regenerative stem cells to dispense insulin for people with diabetes. The deal calls for Evotec SE in Hamburg, Germany to take an €20 million ($CN 27 million, $US 21 million) equity stake in Sernova Corp., in London, Ontario, Canada.

Sernova Corp. is a medical device enterprise creating implanted systems releasing long-term cell therapies that function, in effect, as replacement organs. The company’s technology platform is its cell pouch, a biocompatible device implanted in the body containing cells that generate therapeutic proteins. Sernova says the cell pouch is made of natural tissue, with cylindrical chambers that microencapsulate cells within the pouch to reduce immune rejection, although immune-protective medications are still required.

For people with diabetes, the cell pouch is implanted in the abdominal wall, containing islet or beta cells in the pancreas that produce insulin. An early- and mid-stage clinical trial assessing the system’s safety among individuals with type 1 diabetes is underway at University of Chicago, but also tracking efficacy indicators such as blood glucose levels and hypoglycemic events. Sernova is adapting its cell pouch technology as well for hemophilia A, where individuals do not produce clotting factor 8 to prevent excessive bleeding.

Help people with type 1 and type 2 diabetes

Evotec discovers and develops a wide range of therapies covering metabolic diseases, oncology, neuroscience, pain, inflammation, and infectious diseases. The company works largely through collaborations with drug companies, medical device developers, and research labs providing drug discovery services. One of Evotec’s programs offers induced pluripotent stem cells, or iPSCs, adult cells derived from patients for transformation into functioning cells, as a service for discovering regenerative treatments. The company says it operates multiple iPSC lines that can produce cells in industrial quantities. Evotec says it first partnered with Harvard University’s Stem Cell Institute to develop the service, and later employed by several other drug companies and labs.

Under their agreement, Sernova is incorporating Evotec’s iPSCs that transform into pancreatic beta cells into its cell pouch for people with diabetes. The companies expect their collaboration will result in a cell pouch implant that can help people with both type 1 and type 2 diabetes dependent on regular insulin releases. The goal, say the companies, is to develop an implanted therapy for diabetes that produces an unlimited amount of insulin.

In the deal, Sernova gains access to Evotec’s iPSCs through an option to license the technology to develop treatments for type 1 and type 2 diabetes. Also under the agreement, Evotec is making an immediate €15 million equity investment in Sernova, with another €5 million investment planned for later.

“Together we will progress a highly differentiated first-in-class beta cell therapy into clinical development,” says Cord Dohrmann, chief scientist at Evotec in a statement, “with the common goal to bring a truly transformative therapy to insulin-dependent diabetic patients. The synergies of Evotec’s and Sernova’s technologies puts Sernova in position to become the world’s leader in beta cell replacement therapy.”

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the entire page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Trial Shows Gene Therapy Results with Sickle Cell Disease

Sickle cells illustration

Sickle cells illustration (Open Stax College, wikimedia commons, https://commons.wikimedia.org/wiki/File:1911_Sickle_Cells.jpg)

16 May 2022. Early results from a clinical trial show an experimental gene transfer therapy largely reduces painful events from sickle cell disease for one to two years. Findings from the trial sponsored by the therapy’s developer Aruvant Sciences are scheduled for delivery today at a meeting of American Society of Gene and Cell Therapy in Washington, D.C.

Sickle cell disease is a genetic blood disorder where hemoglobin, a protein in blood that delivers oxygen to cells in the body, causes blood cells to become crescent or sickle shaped instead of their normal round form. The abnormal shape causes blood cells to break down, become less flexible, and accumulate in tiny blood vessels, leading to anemia and periodic painful episodes. Sickle cell disease is prevalent worldwide, and affects some 100,000 people in the U.S., including about 1 in 500 people of African descent, and 1 in 1,000 to 1,400 people of Hispanic descent.

Aruvant Sciences is a four year-old biotechnology enterprise in New York developing gene therapies for rare diseases, beginning with the blood disorders sickle cell disease and beta-thalassemia where people produce lower levels of hemoglobin in their blood. The company is part of collection of businesses created by Roivant Sciences in Basel, Switzerland to develop biomedical technologies. Roivant calls the individual companies “vants” with each of the companies focusing on a particular disease or technology type. Science & Enterprise reported on formation of Aruvant Sciences in Nov. 2018.

Lower chemotherapy doses

The clinical trial is evaluating Aruvant Sciences’ lead product code-named ARU-1801 that uses benign lentiviruses to deliver a modified healthy fetal hemoglobin gene to a patient’s own blood-forming stem cells. In this case, a sample of the patient’s stem cells are extracted from bone marrow, then cultured and transformed into healthy blood-forming cells with functioning genes producing fetal hemoglobin, and infused back into the patient. This process was first developed by Punam Malik, a hematologist at Cincinnati Children’s Hospital studying gene therapies for blood disorders, and licensed to Aruvant Sciences.

The early- and mid-stage trial, led by Malik, is enrolling 10 adults with severe sickle cell disease, or SCD, in the U.S. and Jamaica. Participants first receive a form of chemotherapy to reduce immune-system interference with the ARU-1801 infusions. The company says it uses lower doses of chemotherapy to reduce chances of adverse effects. The study team tracks participants for two years looking mainly for severe or life-threatening adverse effects from the gene therapy, as well as efficacy indicators, such as fetal hemoglobin measures and number of painful episodes from sickle cells blocking blood vessels, called vaso-occlusive events. The study has no control or comparison group.

Results presented today report on four participants in the trial, age 19 to 34, receiving ARU-1801, and followed for 12 to 24 months. Researchers say participants experienced temporary low white blood cell and platelet cell counts for a median period of seven days, but otherwise no serious adverse effects from the chemotherapy or ARU-1801 treatment. In addition, two participants report no painful episodes in the 12 to 18 months following treatment, while two others report 80 and 93 percent fewer events in the 24 months after receiving ARU-1801.

“The data demonstrate,” says Malik in an Aruvant Sciences statement, “that the ARU-1801 gene therapy may not only be able to reduce severe vaso-occlusive events, but also reduce days in the hospital for SCD patients, which could provide a clinically meaningful benefit for patients and help reduce health care costs.”

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Infographic – Synthetic Opioids Driving Overdose Deaths

Chart: Opioid overdose deaths

Click on image for full-size view (Statista)

14 May 2022. While Covid-19 may grab health headlines in the U.S., the opioid epidemic is not going away, and shifting from prescription to synthetic compounds. Data from the Centers for Disease Control and Prevention, and presented in chart form this week by the business research company Statista, show overdose deaths from synthetic opioids accelerating in the U.S.

Provisional data from CDC show for 2021, drug overdose deaths of any kind reached 103,600, exceeding the 100,000 marker for the first time. And those numbers are rising each year, from nearly 68,000 in 2018 to more than 71,000 in 2019, and about 92,500 in 2020. Those numbers include both intentional overdose deaths, such as suicides and homicides, as well as accidental or unintended overdose deaths, with overdose deaths among men far exceeding those for women.

Further data breakdowns from CDC’s National Center for Health Statistics, displayed in Statista’s chart, show sharply rising numbers of overdose deaths from synthetic opioids, rather than prescription drugs or heroin. Fentanyl and other synthetic opioids account for nearly 18 deaths in 100,000 people in the U.S. in 2020, increasing dramatically since 2015. At the same time, the rate of prescription opioid overdose deaths remains relatively stable at about 5 per 100,000 population, and the rate of heroin overdose deaths dropping slightly to about 4 per 100,000.

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Early Trial Data Show Crispr Cancer Therapy Response

Crispr genome edits illustration

(NIH.gov)

13 May 2022. Initial results from a clinical trial show non-Hodgkin lymphoma patients receiving low doses of gene-edited T-cells achieve a clinical response, but with some adverse effects. Caribou Biosciences Inc. in Berkeley, California, reported the results of its experimental therapy code-named CB-010, which the company plans to present next month at a meeting of the European Hematology Association in Vienna, Austria.

Caribou Biosciences uses the gene-editing technology Crispr to create engineered immune-system cells as cancer therapies. The gene editing technology Crispr, short for clustered regularly interspaced short palindromic repeats, is derived from bacterial defense mechanisms using RNA to identify and target precise locations in DNA for editing. One of the company’s founders is Jennifer Doudna, professor of chemistry and biology at University of California in Berkeley, a co-recipient of the 2020 Nobel Prize in chemistry and scientific adviser to the company.

CB-010 is designed with Caribou Bio’s technology known as chRDNAs, pronounced “Chardonnays,” providing more precise DNA targeting than earlier forms of Crispr. The company says chRDNAs use more than RNA alone to find targeted genes, which makes possible more complex editing of T-cells and natural killer cells in the immune system. Caribou says for CB-010 it takes donated T-cells from healthy volunteers, then makes three types of edits in the cells’ genome, inserting chimeric antigen receptors or CARs that target genes coding for original T-cell receptors. Plus, the edits remove checkpoint proteins called PD-1 inhibiting immune responses to cancer, and target the CD19 protein, a characteristic indicator of B-cells found on the cell surface.

Four of five achieve complete response

The early-stage clinical trial is enrolling 50 patients with relapsed or stubborn, non-responsive cases of B-cell non-Hodgkin lymphoma, a cancer of lymph tissue in the immune system, a more common form of non-Hodgkin lymphoma in adults. Participants first are given chemotherapy to remove regulatory T-cells and similar immune cells that could compete with the treatments. The first trial participants are then given escalating doses of CB-010 to find the optimum dosage, and check for adverse effects. The study team is also assessing clinical responses to the treatments. Science & Enterprise reported on the start of the trial in July 2021.

By the 23 Feb. 2022 cut-off date, says Caribou Bio, five of the first six participants in the trial receiving a lower dose of engineered CAR T-cells in CB-010, completed the 28-day post-treatment evaluation period. All of these five individuals, says the company, experienced at least some clinical response to the treatments, with four participants reporting a complete response, indicating disappearance of cancer cells. Those complete responses continued for at least three months at the cut-off date, with one participant experiencing a complete response for six months following treatment.

The company says three of the six participants treated with CB-010 experienced problems from low red-, white, or platelet blood cell counts, or low levels of immunoglobulin antibodies that required medical attention. And one participant reported mild to moderate cytokine and immune effector cell release syndromes that required treatment, with that individual later among the complete clinical responses. No participants experienced graft versus host disease, immune system reactions that reject donated cells.

Caribou Bio says the safety and efficacy results so far support continuing the trial at a higher dose for patients.”CB-010 is the first allogeneic anti-CD19 CAR T-cell therapy in the clinic with a PD-1 knock-out,” says Rachel Haurwitz, Caribou’s president and CEO in a company statement, “a genome-editing strategy designed to limit premature CAR T-cell exhaustion, potentially leading to better tumor debulking and an improved therapeutic index through sustained anti-tumor activity.” Haurwitz adds that the results “represent important steps toward validating our chRDNA genome-editing platform as well as our plans for future development of CB-010 and our broader pipeline.”

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Roche, Global Fund to Build Local Diagnostic Processes

Transporting HIV tests

Transporting HIV tests samples in Nigeria (Anthony Abu, USIAID.gov, Flickr)

12 May 2022. The medical products company Roche is partnering with the Global Fund to develop systems and processes for disease diagnostics in low-resource regions. While the collaboration is expected to last five years, financial and intellectual property terms of the partnership were not disclosed.

Roche is a global developer of drugs and diagnostics based in Basel, Switzerland. In 2014, the company established its global access initiative to expand testing for HIV-AIDS in low-resource regions of the world, in support of the United Nations efforts to combat AIDS. Since then, Roche expanded its global-access program to include tests for tuberculosis, hepatitis B and C, human papillomavirus, and most recently SARS-CoV-2 viruses. Roche says it designed the program to support sustainable local solutions connecting supply chains to point-of-care delivery. The company says its efforts focus on diagnostics and lab testing networks to build capacity and strengthen local health care delivery.

The Global Fund — full name: The Global Fund to Fight AIDS, Tuberculosis, and Malaria — says it raises and allocates more that $4 billion a year to fight these infectious diseases in low-and middle-income countries. The group estimates about 2 billion people are infected with tuberculosis worldwide, with 37 million people living with HIV, of which 6 million are undiagnosed. In addition, says the Global Fund, the Covid-19 pandemic has interrupted HIV and tuberculosis health programs, citing data showing HIV tests declining 22 percent and 100,000 more deaths from tuberculosis occurring in low-resource countries since 2020.

Build more capacity at the local level

The Global Fund, based in Geneva, says it works with individual country governments and civil societies to devise effective interventions addressing HIV-AIDS, tuberculosis, and malaria at the local level. The group says in 2019 to 2021, it allocated about three-quarters of its funds (74%) to Sub-Saharan Africa and 16 percent to the Asia-Pacific region, with the remaining 10 percent divided between Latin America, North Africa, Middle East, Eastern Europe, and Central Asia.

In their collaboration, the Roche global access program and Global Fund plan to build more capacity for HIV and tuberculosis testing at the local level to deliver diagnostics results and better manage medical waste. To meet these goals, the partners expect to develop more effective processes for collection, transporting, and testing patient specimen samples, as well as returning results in time for meaningful interventions.

As part of this program, Roche and the Global Fund say they will address challenges including access to roads, workforce capacity, IT systems, and network infrastructure needed to perform and deliver results for HIV and tuberculosis tests. In addition, the project expects to produce new solutions for medical waste and used testing instruments, to reduce their environmental and economic burdens on local communities. The partners plan to work with government health ministries on implementing new technologies and knowledge transfer in two or three pilot projects, then scale up the program to 10 countries over five years.

“Getting people to test for HIV and TB,” says Global Fund executive director Peter Sands in a Roche statement, “is fundamental to containing transmission and enrolling people on treatment, which are crucial steps to saving lives and ending these diseases as public health threats.” Thomas Schinecker, CEO of Roche Diagnostics adds, “Connecting our experts with critical local stakeholders, we are aiming to help build sustainable solutions that could be scaled across countries.”

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Trial Set for Ingested Colon Cancer Detection Capsule

Detect cancer scrabble

(Marco Verch, Flickr)

11 May 2022. A clinical trial is set to begin assessing an electronic capsule designed to detect and transmit images from the gut to detect early cancer-causing polyps. The study is conducted by the Mayo Clinic in Rochester, Minnesota, and sponsored by Check-Cap Ltd., developer of the system, in Isfiya, Israel.

Check-Cap cites data estimating 1.9 million worldwide cases of colorectal cancer and 935,000 deaths each year, with 150,000 of those cases and 53,000 deaths in the U.S. At the same time, says the company, screening rates for colorectal cancer are low, since colonoscopies, the procedure to screen for the disease, requires extensive preparations to empty the colon, sedation of many patients, and an invasive endoscope. As a result, benign polyps in the colon in many asymptomatic individuals are going undetected, yet could be removed if identified before becoming tumors.

The Check-Cap system, called C-Scan, uses a capsule, small enough to be swallowed, containing a tiny X-ray emitting device and an image contrast agent.  The image contrast agent mixes with colon tissue, which gives off photons or light particles, read by X-ray detectors in the capsule. The close proximity of the capsule to the colon wall allows for low X-ray doses. At the same time, photons given off from the colon interact with electrons in the tissue, changing their direction and energy in measurable ways, a process called Compton scattering.

The capsule captures both sets of photons, and transmits the data to three collection units worn on the torso, where they’re relayed to a workstation. The company’s algorithms and software then process the data and prepare 3-D images of the colon interior surface for physicians, highlighting suspicious regions. Check-Cap says the C-Scan system is not intended to replace colonoscopies, but serves as a preliminary screening step. A positive C-Scan response, says the company, should be followed by a colonoscopy.

Two-part clinical trial

“Detecting precancerous polyps is needed to effectively prevent colorectal cancer,” says Check-Cap CEO Alex Ovadia in a company statement. Ovadia adds, “We believe Check-Cap has the potential to reach those who are deterred by colonoscopy and to help improve colon cancer screening through a patient-friendly solution without the need of bowel cleaning, sedation, and fasting.”

In an early-stage clinical study, reported by Science & Enterprise in Dec. 2019, 45 participants swallowed the C-Scan capsule, then had a colonoscopy to compare results. None of the participants completing the study reported any more than mild adverse effects, and later published results of the trial show the system with a true-positive sensitivity of 78 percent and true-negative specificity of 90 percent.

The new clinical trial is enrolling 952 healthy participants, age 50 to 75, at up to 15 sites in the U.S. In the first part of the study, some 200 participants will test the C-Scan system to help calibrate the device and analytics for average risk of colorectal cancer. In the second part of the trial, remaining participants will use the C-Scan system and receive a colonoscopy to detect precancerous polyps, with a sample size large enough to generate statistically reliable data for FDA’s decision-making needs.

The company expects to complete the calibration part of the trial, and begin the main data-gathering portion, in the fourth quarter of 2022.

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

Small Biz Grant Funds Mental Health App Clinical Trial

Hands covering face

(Victoria Borodinova, Pixabay. https://pixabay.com/photos/cover-your-face-with-your-hands-hide-6599123/)

10 May 2022. National Institute of Mental Health is funding a clinical trial to evaluate a home-based mobile app that works online with a clinician to treat depression. Meru Health in San Mateo, California is the recipient of a $2 million grant from NIMH, part of National Institutes of Health, for the three-year assessment of the company’s solution, with the agency recently awarding $750,000 for the first year of the project.

Meru Health says it uses an holistic mental health therapy approach in a mobile app that combines guidance from a licensed therapist with exercises to learn more productive behaviors and habits, biofeedback such as sleep and heart rate variability, and an online anonymous support group. The 12-week program, says the company, is coordinated from the outset with the participant’s primary medical care provider and can call on a psychiatrist for medication oversight if needed. Meru Health says its app and home-based approach maximizes privacy for people with depression, a disorder that often stigmatizes patients.

The company says a home-based therapy using online technology is needed to keep up with a growing demand for effective mental health services that in many communities is outstripping the supply of licensed clinicians. “We’re currently experiencing a national mental health crisis,” says Meru Health research director Nicholas Peiper in a company statement released through Cision. He adds, “Our program attempts to overcome many barriers to care while making sure that even more people get better and stay better long-term.”

Reductions in depressive and anxiety symptoms

Meru Health cites research showing eight of 10 participants in its program show signs of improvement or recovery. A study in the Journal of Medical Internet Research in June 2021, gives results assessing an eight-week version of the program among a group of 20 older adults, average age of 61. The results show three-quarters of the group completed at least seven of the eight weekly sessions, with reductions in depressive and anxiety symptoms from before to after the program. Nearly half (45%) reported clinically meaningful improvements in depressive or anxiety symptoms. The study had no control or comparison group.

The NIMH grant funds a proof-of-concept assessment of the Meru Health program in advance of a clinical study. Meru Health plans to refine and optimize its app and supporting materials, and test its screening, referral, and enrollment processes to prepare for the trial. The early-stage clinical trial itself plans to enroll some 300 adults with depression at multiple sites, with participants randomly assigned to testing groups to evaluate the program’s effectiveness. The company expects findings from the trial to help guide the design of later studies and provide guidance for further program adjustments.

The award is a Small Business Innovation Research or SBIR grant made under NIH’s small business programs that set aside a part of the agency’s research funding for U.S.-based and owned companies. Most SBIR grants are made in two parts: a first phase to determine technical and commercial feasibility, and a second phase to develop and test a working prototype or prepare for clinical trials. In this undertaking, the two phases a combined into a single project.

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

AI-Aided Collaboration to Discover Neuro Disease Drugs

Mature neuron

(National Institute of General Medical Sciences, NIH)

9 May 2022. Two biotechnology and health technology companies are discovering precision treatments for neurological disorders with simulation models for individual patients. The collaboration brings together Arvinas Inc. in New Haven, Connecticut, a developer of therapies that degrade disease-causing proteins, and GNS Healthcare in Somerville, Massachusetts that uses artificial intelligence algorithms to simulate disease activity in individual patients.

Arvinas and GNS Healthcare seek to discover new therapies for chronic, debilitating neurological disorders such as Parkinson’s, Alzheimer’s, and Huntington’s diseases. Not only do these conditions affect a large number of people, estimated by GNS Healthcare at six million in the U.S., but they also present a range of symptoms and varying progression rates, which suggests a need for more precise and personalized treatments rather than a single therapy.

Arvinas discovers and develops treatments for cancer and neurological diseases that aim to degrade proteins in the body responsible for these diseases. The company’s technology, based on research by its founder Craig Crews at Yale University, and called proteolysis targeting chimeras or Protac, harnesses E3 ligases, a group of proteins in the body that acts as a natural defense against disease-causing mutated or misfolded proteins. E3 ligases, says Arvinas, add a targeting molecule called ubiquitin, sending disease-causing proteins to the proteasome, a cellular complex that breaks down the proteins into smaller peptides.

The company says this mechanism allows for weak binding to target proteins, and in preclinical studies, is shown to cross the blood-brain barrier. Arvinas has several therapy candidates for neurodegenerative diseases still in early-stage research, to go along with a number of cancer therapies in preclinical and clinical development.

Causal factors, not just associations

GNS Healthcare helps biotech and pharmaceutical companies discover new therapies with a technology called “virtual patients” using simulation algorithms to represent individual patients. The company draws on data for its algorithms from a host of large-scale databases representing genomics, electronic health records, demographics, pharmacy and medical claims records, imaging, and mobile devices. Aggregating these individual patient models, says GNS Healthcare, reveals causal factors and not just associations in the data.

The company says its work already uncovered 10 new and unique targets for Alzheimer’s disease treatments, by reverse-engineering networks linking gene expressions, metabolites, and clinical data. In Sept. 2017, Science & Enterprise reported on an analysis of data from two clinical trials by GNS Healthcare, where its machine-learning algorithms identified factors that predict the decline of motor functions in individuals with Parkinson’s disease.

In their collaboration, Arvinas and GNS Healthcare are applying their respective processes to discover new drugs using the Protac technology of protein degradation for treating neurodegenerative diseases. The collaboration aims to better understand the workings of protein degradation therapies in individual patients, as well as model those findings in simulated clinical trials. Data from simulated trials are expected to highlight possible clinical outcomes, better identify patients for trials, and connect treatment options to different types of patients.

“We believe this collaboration,” says Arvinas vice president for neuroscience and platform biology Angela Cacace in a GNS Healthcare statement, “will provide novel insights and will help us understand the underlying mechanisms of complex neurodegenerative diseases to inform our discovery and development efforts with the aim of improving patient outcomes.”

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *

 

What Do You Need in a Business Space?

– Contributed content –

Conference table

(Social.Cut, Unsplash. https://unsplash.com/photos/1RT4txDDAbM)

7 May 2022. A business space is a physical or virtual place where businesses conduct their transactions. It is a place that is designed to serve the needs of the business. Having the right business space can make or break your company’s success. There are certain factors that must be considered before you decide to start a new business. These include location, size, and amenities. You should also consider the cost of leasing or purchasing your business space.

The Importance of Setting Up a Great First Impression with your Business Space

First impressions are important when it comes to the success of your business, and you should take into consideration how your space looks and feels, what it smells like, as well as the overall vibe. Not only that, but first impressions are the first and most important impression that a customer gets about your business. They are also the most difficult to change. Setting this with the space can help.

The Problems with Buying a Business Space

Buying a business space is an expensive decision. Not only do you have to pay for the space but also for the equipment that you need in order to run your business. If you are not sure whether it is worth buying a business space or not, there are plenty of other options that you can choose from. You can rent a business office instead of buying one. So, if you are looking to start your own company, renting a place near your work would be more cost-effective than buying one outright

What You Really Need in A Business Space

The purpose of the premises is to provide a safe and healthy working environment for their employees. It should be spacious enough to accommodate all the employees and have all the necessary facilities. The most important thing you need in a business space is enough space for your staff to work collaboratively and make sure that you have enough room for expansion. But it also needs to be secure. This is where an access control system and a security camera comes in. Finally, there’s also ensuring that you have the right facilities too

How to Find the Perfect Larger Space for Your Small Business Needs

If you are in the process of building your business, it is likely that you have a lot of things to do and not enough time to do them. Finding space for your business can be difficult especially if you are running a small business. You need to find the perfect space that can accommodate both your needs as well as your budget. For this, it helps for you to do research on local businesses and their size and compare that with yours. If they are bigger than what you need, then it is likely that they have a larger space available for rent or lease. You can also try renting out a storage unit or warehouse in order to see if there is any room left before making a final decision on where you will move.

*     *     *